Today’s US Food and Drug Administration (FDA) approval is a special day for the metastatic breast cancer community.
It marks the culmination of years of hard work in studying how to improve treatment for metastatic breast cancer, which impacts the lives of too many.
This approval milestone did not happen overnight, and it took a village – so to speak.
As Bruno Strigini, CEO, Novartis Oncology, explains below, this important new treatment option underscores the dedication and commitment of countless patients, researchers, physicians, nurses, social workers, and institutional teams who participated in and supported the clinical trial research.
Here at Novartis, patients inspire and motivate us to revolutionize research and develop new medicines with the goal of helping to improve and extend lives.